GC
CLDX icon

Guggenheim Capital’s Celldex Therapeutics CLDX Stock Holding History

Guggenheim Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,721
Closed -$588K – 1769
2025
Q3 		$588K Sell
22,721
-3,274
-13% -$75.9K ﹤0.01% 1118
2025
Q2 		$529K Buy
25,995
+1,212
+5% +$23.6K ﹤0.01% 1159
2025
Q1 		$450K Buy
24,783
+986
+4% +$22K ﹤0.01% 1244
2024
Q4 		$601K Buy
+23,797
New +$647K ﹤0.01% 1180
2017
Q3 		– Sell
-1,235
Closed -$44K – 2807
2017
Q2 		$44K Sell
1,235
-197
-14% -$8.71K ﹤0.01% 2742
2017
Q1 		$77K Sell
1,432
-141
-9% -$7.34K ﹤0.01% 2709
2016
Q4 		$84K Sell
1,573
-140
-8% -$7.96K ﹤0.01% 2780
2016
Q3 		$104K Sell
1,713
-202
-11% -$12.6K ﹤0.01% 2724
2016
Q2 		$127K Sell
1,915
-247
-11% -$15.7K ﹤0.01% 2710
2016
Q1 		$123K Sell
2,162
-18,346
-89% -$2.06M ﹤0.01% 2747
2015
Q4 		$4.82M Sell
20,508
-7,119
-26% -$1.55M 0.01% 1034
2015
Q3 		$4.37M Buy
27,627
+3,942
+17% +$1.12M 0.01% 1116
2015
Q2 		$8.96M Buy
23,685
+5,881
+33% +$2.34M 0.02% 885
2015
Q1 		$7.44M Sell
17,804
-853
-5% -$305K 0.02% 981
2014
Q4 		$5.11M Buy
18,657
+1,761
+10% +$438K 0.01% 1111
2014
Q3 		$3.29M Buy
16,896
+2,525
+18% +$550K 0.01% 1421
2014
Q2 		$3.52M Sell
14,371
-1,520
-10% -$343K 0.01% 1396
2014
Q1 		$4.21M Buy
15,891
+2,834
+22% +$1.09M 0.01% 1223
2013
Q4 		$4.74M Buy
13,057
+2,386
+22% +$919K 0.01% 1116
2013
Q3 		$5.67M Sell
10,671
-2,177
-17% -$746K 0.02% 1038
2013
Q2 		$3.01M Buy
+12,848
New +$2.53M 0.01% 1305

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Guggenheim Capital's CLDX Position: Q4 2025 in Review

Guggenheim Capital sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 22,721 shares — an estimated $588K sold.

Guggenheim Capital first reported a position in CLDX in Q2 2013 and held it in 21 quarters. The position peaked at $8.96M in Q2 2015. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • Guggenheim Capital reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Guggenheim Capital sold 22,721 Celldex Therapeutics shares in Q4 2025, an estimated $588K.
  • Guggenheim Capital first reported a position in Celldex Therapeutics in Q2 2013 and held it in 21 quarters.
  • Guggenheim Capital's Celldex Therapeutics position peaked at $8.96M in Q2 2015.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Guggenheim Capital's 13F filing for Q4 2025, filed 17 Feb 2026.